Comparative Efficacy of Octreotide Andterlipressin in the Treatment of Esophageal Variceal Bleeding

Dr. R. K. Chaitanya Reddy, Dr. R. Selva Sekaran, Dr. R. Ramasubramanian, Dr. Shirish .N .D

Abstract: Background: To compare the efficacy of Terlipressin and Octreotide in control of acute esophageal variceal bleeding. Methods: In this comparative study 80 patients presenting with acute variceal bleed, during a period of one year( from August 2020 to July 2021), were selected. Patients were divided into two groups of 40 each by lottery method. Group A received Terlipressin, while Group B received Octreotide. Patients in these groups were matched for age, gender, grade of esophageal varices, and Childs-Pugh Class. The outcomes were recorded in terms of control of bleeding, rebleeding or death. Results: Out of 80 patients, 55% were male. Bleeding stopped within 48 hours in 78.75 % of patients (90% in group A vs 70 % in group B). Active bleeding continued in 5% vs 10% in group A and B respectively. Rebleeding after 48 hours was observed in 1.25% vs 3.75% patients in group A and B respectively. No death occurred in group A while one patient died in group B (0% vs 1.25%). The relative risk of continuous bleeding was 2.0 times more in group B as compared to group A, 95% confidence interval 0.867 to 10.014. Conclusions: Patients who were given Terlipressin had better control of bleeding, reduced risk of rebleeding, death as compared to those who were given Octreotide.

Keywords: Octreotide, Terlipressin, Liver Cirrhosis, Portal hypertension, Esophageal Variceal bleed

How to Cite?: Dr. R. K. Chaitanya Reddy, Dr. R. Selva Sekaran, Dr. R. Ramasubramanian, Dr. Shirish .N .D, "Comparative Efficacy of Octreotide Andterlipressin in the Treatment of Esophageal Variceal Bleeding", Volume 11 Issue 6, June 2022, International Journal of Science and Research (IJSR), Pages: 1085-1089, https://www.ijsr.net/getabstract.php?paperid=SR22616190600, DOI: https://dx.doi.org/10.21275/SR22616190600